Get the Stockscreener App
43.47
0.89%
-0.39
After Hours:
43.47
Qiagen Nv stock is traded at $43.47, with a volume of 1.92M.
It is down -0.89% in the last 24 hours and up +2.69% over the past month.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
See More
Previous Close:
$43.86
Open:
$43.19
24h Volume:
1.92M
Relative Volume:
0.68
Market Cap:
$8.98B
Revenue:
$2.10B
Net Income/Loss:
$402.17M
P/E Ratio:
22.46
EPS:
1.9357
Net Cash Flow:
$403.87M
1W Performance:
+0.84%
1M Performance:
+2.69%
6M Performance:
-7.27%
1Y Performance:
-7.59%
1-Day Range:
$42.79
$43.66
1-Week Range:
$42.57
$44.91
52-Week Range:
$32.53
$57.81
Qiagen Nv Stock (QGEN) Company Profile
Compare QGEN vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QGEN
Qiagen Nv
|
43.47 | 9.27B | 2.10B | 402.17M | 403.87M | 1.9357 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Qiagen Nv Stock (QGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-22-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Jun-24-25 | Initiated | Barclays | Overweight |
| Apr-04-25 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Feb-19-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-06-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-10-24 | Upgrade | Jefferies | Hold → Buy |
| Oct-17-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jun-27-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Dec-07-23 | Upgrade | Goldman | Neutral → Buy |
| Sep-12-23 | Initiated | Robert W. Baird | Outperform |
| May-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-18-22 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-18-22 | Upgrade | DZ Bank | Hold → Buy |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Oct-14-21 | Initiated | Redburn | Buy |
| Jul-14-21 | Downgrade | Kepler | Buy → Hold |
| Jun-03-21 | Initiated | Goldman | Neutral |
| Oct-06-20 | Resumed | BofA Securities | Buy |
| Sep-28-20 | Upgrade | Kepler | Hold → Buy |
| Aug-24-20 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-20 | Resumed | JP Morgan | Overweight |
| Aug-17-20 | Upgrade | Berenberg | Hold → Buy |
| Aug-14-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-14-20 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-04-20 | Downgrade | Berenberg | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Dec-26-19 | Resumed | BofA/Merrill | Underperform |
| Nov-15-19 | Initiated | Stifel | Hold |
| Nov-14-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-14-19 | Upgrade | JP Morgan | Underweight → Overweight |
| Nov-14-19 | Upgrade | Kepler | Reduce → Hold |
| Oct-17-19 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-09-19 | Downgrade | Kepler | Hold → Reduce |
| Oct-08-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-19 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-08-19 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Qiagen Nv Stock (QGEN) Latest News
Qiagen stock edges lower as investors look beyond recent earnings - AD HOC NEWS
New CEO took over the reins - European Biotechnology Magazine
Qiagen stock heads into the open after a muted move on Xetra - AD HOC NEWS
Public Employees Retirement System of Ohio Purchases New Shares in Qiagen N.V. $QGEN - MarketBeat
Qiagen (QGEN) Beat Q2 Estimates And Reaffirmed Outlook, Is It Still Below Fair Value? - Yahoo Finance
Qiagen N.V.ADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen stock trades around 43 dollars as investors watch margins and diagnostics demand - AD HOC NEWS
Qiagen (QGEN) Up 5.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Global Multiplex Assays Market 2026 Edition - GlobeNewswire Inc.
Qiagen stock holds steady as margins and stake disclosure support valuation - AD HOC NEWS
BlackRock Discloses Significant Stake in Qiagen Under AFM Rules - The Globe and Mail
Qiagen stock holds near 43 dollars as stake disclosure and margins support valuation - AD HOC NEWS
Qiagen stock holds near 43 dollars after steady analyst view - AD HOC NEWS
Release according to Article 40, Section 1 of the WpHG - TradingView
Qiagen NV at Citi Global Healthcare Conference Transcript - GuruFocus
Qiagen stock steadies near 43 dollars as latest quarter shows modest growth - AD HOC NEWS
Q3 2025 Qiagen NV Earnings Call Transcript - GuruFocus
Qiagen stock holds mid-40 dollar level as analysts stick to hold ratings - AD HOC NEWS
Plant Virome Diagnostics Outlook 2026-2030 Featuring Profiles of Illumina, Thermo Fisher Scientific and Qiagen - Yahoo Finance
Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
List of 26 Acquisitions by Qiagen (Sep 2026) - Tracxn
Qiagen stock steadies around $43 as investors digest legal and ownership signals - AD HOC NEWS
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
Qiagen N.V. (QGEN) Stock Analysis: Navigating Potential Upside In Healthcare Diagnostics - DirectorsTalk Interviews
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
Wellington Management Group LLP Trims Stock Position in Qiagen N.V. $QGEN - MarketBeat
Goldman Sachs Revealed as 2.97% Shareholder in Qiagen via AFM Filing - The Globe and Mail
Bank of America Reports 4.69% Stake in Qiagen - The Globe and Mail
Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market? - Yahoo Finance
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics Announces $4.8 Million Award in Patent Case Against Qiagen Unit - marketscreener.com
QIAGEN Launches QIAsymphony Connect for Automated Nucleic Acid Extraction - Clinical Lab Products
Qiagen launches automated nucleic acid extraction platform - Investing.com
Zacks Research Has Pessimistic Outlook of Qiagen Q3 Earnings - MarketBeat
QIAGEN Names Former Beckman Coulter President as CEO - Medical Product Outsourcing
Two potential buyers begin formal due diligence in Qiagen sales processreport (QGEN:NYSE) - Seeking Alpha
Qiagen N.V. Appoints Jonathan M. Pratt as Chief Executive Officer, Effective September 1, 2026 - marketscreener.com
QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer - marketscreener.com
Qiagen names Jonathan Pratt as CEO amid takeover talks - Investing.com
Wellington Discloses 5.1% Voting Stake in Qiagen via AFM Filing - The Globe and Mail
Qiagen stock trades just below analyst target as latest earnings underpin valuation - Ad-hoc-news.de
Qiagen stock slips despite Q2 earnings beat and stable guidance - Ad-hoc-news.de
Qiagen stock holds steady as recent earnings support valuation - Ad-hoc-news.de
PTA-AFR: QIAGEN N.V.: Pre-announcement of a financial report according to articles 114117 WpHG - TradingView
Qiagen stock advances after topping DAX winners with fresh gain - Ad-hoc-news.de
Qiagen stock holds steady as merger terms clarify for investors - Ad-hoc-news.de
Qiagen NV (QGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Qiagen NV at Leerink Global Healthcare Conference Transcript - GuruFocus
Qiagen NV Annual Shareholders Meeting Transcript - GuruFocus
Qiagen (QGEN) Price Action: Loses 0.66% to Close at $42.32 on the Day; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionQuote Data - vinanet.vn
Qiagen Nv Stock (QGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):